14results about How to "Long retention time" patented technology

The invention discloses a non-derivatization quantitative detection method for amino acid in a high-concentration protein preparation, which comprises the following steps: separating by using a graphitized carbon chromatographic column, adding an ion pair reagent trifluoroacetic acid into a mobile phase, and detecting by using an electric fog detector (CAD); the method comprises the following steps: preparing a plurality of groups of amino acid standard substance solutions with different concentration groups, wherein the concentration range is 1mmol / L-20mmol / L; drawing a quadratic equation standard curve of the amino acid standard product concentration and the peak area as a detection equation for detecting the amino acid concentration; the method comprises the following steps: diluting a test sample by using ultrapure water for multiple times, carrying out ultrafiltration centrifugal treatment, removing protein, introducing the sample, obtaining a corresponding peak area according to the spectrum integral of the test sample, and substituting the peak area into the detection equation to obtain the concentration of amino acid in the test sample. The method has the advantages of high detection precision, high detection efficiency and simple operation, and greatly reduces the adverse effect of high-concentration protein on the chromatographic column.

The invention relates to the technical field of biomedical materials and tissue engineering, and discloses sequential slow-release temperature-sensitive hydrogel and a preparation method and application thereof.The preparation method comprises the following steps that a blood sample is subjected to programmed centrifugation, and a gel layer of leukocyte-rich platelet-rich fibrin L-PRF and a gel layer of improved platelet-rich fibrin A-PRF are obtained respectively; and the gel layer is cut into pieces, pre-frozen, freeze-dried, ground and sieved, so that L-PRF freeze-dried powder and A-PRF freeze-dried powder are obtained respectively, and the methacrylic acid gelatin microspheres entrapped with the L-PRF freeze-dried powder are prepared. The microspheres and A-PRF freeze-dried powder are loaded into a temperature-sensitive hydrogel system composed of chitosan, polygalacturonic acid and sodium beta-glycerophosphate, so that the growth factors can be effectively entrapped in the hydrogel structure, and continuous release is realized; the system has good mechanical strength and structural stability, the retention time of the material in vivo is prolonged, and stable three-dimensional network support is provided.

The invention provides powder containing a bridge structure, a preparation method of the powder, application of the powder in anti-darkness liquid foundation and a product, and relates to the technical field of cosmetics. The invention provides a powder containing a bridge structure, the powder comprises submicron polymer spheres, a coloring agent, a powder modifier, a surface gloss treating agent and an antioxidant, and the powder can be used for preparing an anti-darkness liquid foundation. The anti-darkness liquid foundation composed of water, the bridge-type structure powder prepared by the invention, a film-forming agent, an emulsifier, an oil phase component, a matrix and other components can achieve the makeup feeling of good anti-darkness effect and no powder floating during makeup.

The invention relates to a controlled-release linalool emulsion based on a ternary system as well as a preparation method and application of the controlled-release linalool emulsion. The linalool emulsion is an oil-in-water Pickering emulsion composed of a water phase and an oil phase, the water phase comprises a ternary system composed of soybean protein isolate, pectin and hydroxypropyl methyl cellulose, and the oil phase is linalool essential oil. The preparation method comprises the following steps: respectively preparing soybean protein isolate, pectin and hydroxypropyl methyl cellulose solutions, and mixing to obtain a ternary composite water phase; and mixing the ternary composite water phase with the oil phase, and carrying out high-pressure homogenization treatment and ultrasonic treatment under a low-temperature condition to obtain the controlled-release linalool emulsion based on the ternary system. Compared with the prior art, the linalool essential oil emulsion embedding method solves the problem that linalool is easy to volatilize, and can be used in the fields of fruit and vegetable fresh keeping, tea fragrance maintaining and the like.

The invention discloses a nasal mucosa microneedle vaccine delivery system capable of inducing mucosa immunity and a preparation method and application of the nasal mucosa microneedle vaccine delivery system. The administration mode of vaccines is nasal mucosa microneedle vaccine delivery. The soluble layered microneedle is characterized in that a needle body is inspired by a hunting claw, a leopard-claw-shaped needle tip is designed, and the needle tip is bent; the strategy is proved to be capable of inducing potent antigen-specific immune response in mucous membrane tissues. The technology can be widely applied to research and development of novel mucosal vaccines for preventing respiratory tract infection pathogens (such as influenza viruses and the like).

The application provides a surface-modified gadolinium-based covalent organic framework magnetic resonance contrast agent and a preparation method and application thereof, characterized in that: tetra-(p-aminophenyl porphyrin) is used as a monomer to prepare Gd(III)-porphyrin, and then the Gd-porphyrin-based covalent organic framework polymer Gd-PCOFs contrast agent is connected by forming an imine bond with a dialsyl compound. Then, the surface of the Gd-PCOFs is modified by a molecule containing a mercapto group, so that a magnetic resonance contrast agent with uniform particle size and good dispersity is obtained, and the longitudinal relaxation rate can reach 126.35 s ‑ 1 mM ‑1 , which can be used for super-sensitive magnetic resonance imaging of solution, cells and living bodies.

A non-volatile memory cell (200) is disclosed comprising a pinch-off ferroelectric memory FET (40) and at least one select device (80), said at least one select device (80) being electrically connected in series to the pinch-off ferroelectric memory FET (40).

Provided is a cinnamyl aldehyde-loaded solid-liquid biphasic artificial cell (SL-BACs) which has a solid-phase protective film and a liquid multicore, and which is efficiently and stably produced using a microfluidic T-type chip. The SL-BACs can provide multi-aspect treatment assistance for colitis induced by salmonella typhimurium. Firstly, an aptamer in a liquid multinuclear shows accurate targeting at an infected part; secondly, the encapsulation efficiency of the SL-BACs on the cinnamyl aldehyde is relatively high, and is about 82.9 percent; thirdly, the intestinal retention time of the SL-BACs is prolonged to 15 h through the membrane structure; in addition, the SL-BACs show pH responsiveness, liquid multi-core antibiosis is controlled to be released, and the sterilization rate is 95.28%. The SL-BACs can also reduce the secretion of proinflammatory cytokines, optimize the composition of intestinal microbiota and maintain the steady state of the intestinal tract. In a word, the SL-BACs provide necessary conditions for modularizing the artificial cells into an oral system for targeted therapy.

The invention provides a drug-loaded nanoparticle Corr (at) PDA-PEG (at) CD11b and a preparation method and application thereof.The preparation method comprises the following steps that S1, a cordycepin solution and a PDA aqueous solution are mixed, so that cordycepin and PDA form a compound Corr (at) PDA through the pi-pi stacking effect; s2, carrying out PEG (Polyethylene Glycol) modification on the obtained compound Cor(at) PDA to prepare a compound Cor(at) PDA (at) PEG; and S3, dispersing the obtained Corr (at) PDA (at) PEG in a buffer solution, adding an anti-CD11b antibody, reacting for 24 hours, centrifuging, washing, collecting precipitate, and drying to obtain Corr (at) PDA-PEG (at) CD11b. The prepared drug-loaded nanoparticles Corr (at) PDA-PEG (at) CD11b provide a new thought and a new direction for treatment of sepsis-related lung injury, controlled release of cordycepin is realized through the characteristics of the PDA nanoparticles, the problem that cordycepin enters a body and is quickly oxidized and inactivated is avoided, the bioavailability of the cordycepin is improved, and the drug-loaded nanoparticles are suitable for clinical application. By means of immune cell surface specific antibodies and physiological characteristics, rapid chemotaxis recruitment is carried out at the early stage of acute inflammation, rapid and accurate drug targeting is achieved, and sepsis lung injury is relieved.

The application discloses an InGaN nanocolumn-based optoelectronic memristor and a preparation method and application thereof. The composition of the InGaN nanocolumn-based optoelectronic memristor comprises a substrate, an InGaN functional layer, a first Schottky contact electrode and a second Schottky contact electrode, the InGaN functional layer is arranged on the surface of the substrate, the InGaN functional layer is composed of a plurality of InGaN nanocolumns epitaxially grown on the surface of the substrate, and the first Schottky contact electrode and the second Schottky contact electrode are arranged on the side of the InGaN functional layer away from the substrate. The InGaN nanocolumn-based optoelectronic memristor has the advantages of stable resistance state change, long resistance state retention time and the like, is suitable for neural network algorithm and image recognition application, and has simple structure and simple preparation process, and is suitable for large-scale industrial production and application.

The invention relates to the technical field of dressing preparation, and discloses a process for loading benzalkonium chloride on a dressing pad, which comprises the following specific steps: step 1, proportioning dextran according to a ratio of 1: 3, then stirring for 2 hours at 60 DEG C by using a shear type emulsifying machine so that the dextran and the benzalkonium chloride are uniformly mixed to form 100g / L water, then distilling and concentrating under reduced pressure at 45-65 DEG C to form a concentrating agent, then the concentrated solution is poured into a mold with a Teflon anti-sticking coating to be coated into a film, the thickness of the Teflon anti-sticking coating is 45 + / -5 microns, the coated mold is put into a vacuum oven to be baked for 3 hours at the temperature of 60 DEG C, and a glucan film is obtained for standby application after demolding; according to the preparation method, the loading capacity of the BZK in the dressing pad can be remarkably improved, the loading capacity is ensured to reach an expected target value, the stability of the BZK is greatly improved, the retention time of the BZK in the dressing pad is prolonged, the antibacterial property is lasting and effective, the biocompatibility reaches an excellent level, and no irritant and toxic reaction is ensured when the dressing pad is in contact with a human body.

The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is -(X)n-(CH2)m-(Y)q-, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with -O-, -NH(CO)-, or -(CO)-NH-; L2 is -(CH2)p-, p is an integer from 0 to 30, and each CH2 may be individually substituted with -O-, -NH(CO)-, or -(CO)-NH-; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound. The compound and the radiolabeled complex have appropriate blood circulation time, high uptake in tumors and long retention time, and are suitable for nuclide therapy and imaging of tumors with high expression of PSMA.

This invention pertains to materials technology and specifically provides a method for preparing modified polydimethylsiloxane, comprising the following steps: (A1) obtaining the content y of polyether-modified heptamethyltrisiloxane based on the contact angle θ and mapping relationship, and determining the content x of the organic phase in the solution and whether plasma cleaning is required; (A2) mixing polydimethylsiloxane, a curing agent, and polyether-modified heptamethyltrisiloxane, stirring, and reacting, with the content of polyether-modified heptamethyltrisiloxane being y; (A3) loading the reacted mixture into a mold and curing; (A4) performing plasma cleaning according to the requirements of step (A1). This invention has advantages such as simple process and can be applied to fields such as cell culture and biosensors.

The application provides a drug-loaded nanoparticle Cor@PDA-PEG@CD11b and a preparation method and application thereof, the preparation method comprises the following steps: S1, mixing cordycepin solution and PDA aqueous solution, so that the cordycepin and the PDA form a complex Cor@PDA through π-π stacking effect; S2, the obtained complex Cor@PDA is modified by PEG to prepare a complex Cor@PDA@PEG; S3, the obtained Cor@PDA@PEG is dispersed in a buffer solution, and an anti-CD11b antibody is added; after reacting for 24h, centrifugation, washing, collecting the precipitate, and drying, the Cor@PDA-PEG@CD11b is obtained. The drug-loaded nanoparticle Cor@PDA-PEG@CD11b prepared by the application provides a new idea and direction for the treatment of sepsis-related lung injury; through the characteristics of the PDA nanoparticles, the cordycepin is released in a controlled manner, and the problem that the cordycepin is rapidly oxidized and inactivated after entering the body is avoided, the bioavailability is improved, the specific antibodies on the surface of immune cells and the physiological characteristics are utilized, the immune cells are quickly and chemotactically recruited to the inflammatory injury site in the early stage of acute inflammation, the drug is quickly and accurately targeted, and the sepsis lung injury is reduced.